Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GAO on infant formula

This article was originally published in The Tan Sheet

Executive Summary

The Secretary of Agriculture should educate states on the restriction against using the Women, Infants & Children (WIC) acronym and logo in infant formula ads, a Feb. 8 Government Accountability Office report states. USDA also should ensure the restriction is included in all state formula contracts, GAO adds. The recommendation was formed as a result of the office's review of the potential impact of infant formula marketing on breastfeeding rates. The report finds breastfeeding rates in both WIC and non-WIC infants fall short of most national goals, with lowest rates for WIC infants. GAO also finds that although infant formula marketing targeted non-WIC mothers, advertising also reached mothers in the WIC population, and some of the marketing used the WIC logo and acronym in advertising. Additionally, most studies evaluated by the report showed that mothers who were given free formula at hospital discharge were less likely to breastfeed. Breastfeeding can provide infants with protection against infectious diseases and chronic health problems as well as reduce the mother's risk of developing certain cancers, GAO states...

You may also be interested in...

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

COVID-19 Will Forever Change Workplace, But Not Necessarily For The Better, Merck’s Frazier Says

Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts